Publix has recalled baby food due to lead levels. What shoppers should know
Publix announced the recall on its website on May 9 and it applies to all 1,404 stores in the Lakeland-based chain. The U.S. Food and Drug Administration posted its recall announcement on Thursday.
The problem with lead
Exposure to lead, even small amounts, can be harmful to children, especially those ages 6 and younger, according to the U.S. Centers for Disease Control and Prevention. Lead can harm the brain and nervous systems and lead to developmental problems like growth and speech.
What to look for
The recalled baby food comes in 4-ounce pouches of GreenWise Pear, Kiwi, Spinach & Pea Baby Food with a best by date of 11/1/2025. The Global Trade Item Number (GTIN) is 41415-00901.
Bowman Andros produced and distributed the baby food from its Virginia plant for Publix.
Where was the baby food sold?
The Pear, Kiwil, Spinach & Pea Baby Food was sold in the eight states Publix has stores in: Florida, Georgia, Alabama, Tennessee, South Carolina, North Carolina, Virginia and Kentucky.
How did Publix find the problem?
Publix discovered the problem in North Carolina and initiated the recall after routine sampling discovered elevated amounts of lead.
North Carolina agricultural officials found levels at 13.4 parts per billion in the samples, according to ABC News. In January, the FDA offered a guidance report that recommended a limit of 10 parts per billion for products intended for babies and young children.
'As part of our commitment to food safety, potentially impacted products have been removed from all store shelves,' Publix Director of Communications Maria Brous said in the FDA recall announcement. 'To date, there have been no reported cases of illness.'
What you should do
Consumers who have purchased the GreenWise Pear, Kiwi, Spinach & Pea Baby Food may return the pouches to their local store for a full refund, Brous said.
Publix customers with additional questions can call the customer care department at 800-242-1227.
Target baby food recall
Miami's Fruselva USA recalled two lots of Good & Gather baby Pea, Zucchini, Kale & Thyme Vegetable Puree that it manufactures for Target stores nationwide in March. The concern? The possibility it contained too much lead.
That Target baby food recall covered lot Nos. 4169 with a best by date of Dec. 9, 2025, and 4167 with a best by date of Dec. 7, 2025. About 25,600 4-ounce bowls were in that recall.
Miami Herald reporter David J. Neal contributed to this report.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Health Line
an hour ago
- Health Line
What to Know About Homeopathic Remedies for Eczema
Key takeaways Relying solely on homeopathic remedies for eczema may not provide adequate relief. Studies show inconsistent or nonsignificant results compared to placebos. Although scientific backing is limited, homeopathic remedies like dulcamara, graphites, pine tar, and sulfur may help you manage eczema symptoms like itching, inflammation, and skin hydration. Health organizations and the FDA caution against using homeopathy for eczema due to limited safety and efficacy data. Consult a healthcare professional for proven treatments like antihistamines and steroids. Many people with eczema find it challenging to manage the condition. Because eczema is chronic and causes intermittent flare-ups, some people seek different interventions — including alternative treatment approaches like homeopathy. But can homeopathy treat or cure eczema? Homeopathy is a form of complementary or alternative medicine that uses small, diluted doses of a natural substance that causes symptoms to treat those symptoms. The belief is that if large quantities of a substance cause symptoms of a disease, a small, properly diluted amount can help the body heal itself. Some people tout homeopathy as a remedy for eczema, an inflammatory skin condition that affects an estimated 223 million people worldwide. But there's hardly any solid scientific evidence that supports the use or effectiveness of homeopathy for treating eczema. Read on to find out what research says about the use of homeopathy for eczema, if homeopathic products are FDA-approved, and the potential risks of using homeopathy for eczema. Can homeopathy help treat eczema? One of the earliest studies on homeopathy for eczema was a 2009 study by German researchers. The study compared the effects of homeopathic remedies versus placebo in young adults ages 18–35 with eczema. The study found no significant difference between the group that received homeopathy and the group that received a placebo. A later review of studies analyzed evidence from controlled clinical trials for homeopathic treatment for all types of eczema. The research indicated that no evidence from the controlled trials proved the efficacy of homeopathy for treating eczema. A more recent, small 2022 preliminary study noted a slight improvement in eczema symptoms among people who used homeopathy compared to placebo, but the difference was not statistically significant. This means the researchers weren't confident that the slight improvement they observed wasn't by chance. Some homeopathy advocates believe homeopathy can help relieve stress and anxiety, which triggers eczema flare-ups in some people. But a systematic review has shown inconsistent results for its effectiveness in treating anxiety. What do the experts say? The U.S.-based National Eczema Association and U.K.-based National Eczema Society both caution that there's not enough research to support using alternative treatments like homeopathy. Other international organizations like the Polish Dermatological Society also don't recommend using homeopathy for treating eczema. What homeopathic remedies do people use to treat eczema? Although the National Eczema Association cautions that there's not enough research to support alternative therapies like homeopathy, it notes that about half of people with eczema use these treatments. Here are some homeopathic remedies some people believe can help with eczema: Dulcamara Dulcamara, also called woody nightshade, is a shrubby perennial plant from the Solanaceae family. It's a medicinal plant touted for treating skin conditions. While scientific evidence for this is sparse, 2021 research indicated that the plant is rich in alkaloids, has antibacterial properties, and is traditionally used for relieving mild recurrent eczema. Graphites Graphite is a carbon compound similar to coal. Some people use it to treat dry, cracked, itchy, red skin, as occurs in eczema. A 2020 case report revealed that graphite helped reduce eczema symptoms after several weeks of treatment. Pine tar (pix liquida) Studies suggest a potential benefit of using pine tar to treat skin conditions like eczema and psoriasis. People produce pine tar by high-temperature carbonization of the pine tree wood. A 2022 study suggested it may help relieve eczema symptoms, reduce inflammation, and lower the risk of infection. Sulfur Other remedies Other homeopathic remedies with little to no scientific backing include: Rhus toxicodendron sepia natrum muriaticum mezereum lycopodium Arsenicum album Calcarea carbonica Mercurius solubilis barberry (Berberis vulgaris) Are homeopathic products FDA-approved? The Food and Drug Administration (FDA) does not approve any homeopathic product for treatment because the agency has not determined that such products meet effectiveness, safety, and quality standards. What are the risks of homeopathy for eczema? An older review of case reports reported the following side effects of homeopathy: allergic reaction widespread skin irritation nausea and vomiting skin itching hair loss sneezing and inflammation of the nasal cavity lining (rhinitis) Also, keep the following in mind when using homeopathic products: No government body or agency legally regulates homeopathic practitioners. This means a person without qualifications can claim to be a homeopath. There's no strong scientific evidence that homeopathy is safe or effective for eczema. Some homeopathic products may contain high amounts of substances that are not good for your health. A homeopathic product may interfere with your doctor's prescribed medication, reducing its efficacy or causing side effects. What natural and alternative treatments can help with eczema? Some natural treatments that may help manage eczema include: Acupuncture: Acupuncture, part of Traditional Chinese Medicine (TCM), may help reduce skin itching, wheal size, and allergic reaction in people with eczema. Aloe vera: Aloe vera is a plant rich in antioxidants that can help heal wounds, regenerate damaged skin, and retain skin integrity. Coconut oil: Some people with eczema may benefit from coconut oil because it has antimicrobial and anti-inflammatory properties, hydrates the skin, reduces itching, and reduces the chances of infection. Colloidal oatmeal: Colloidal oatmeal is oat grain ground into a fine powder. It can help your body retain moisture and relieve dry, itchy skin. Honey: Researchers have observed several properties of honey that may help people with eczema, but more research is needed. Massage therapy: A gentle, 20-minute massage using a moisturizer may help reduce eczema symptoms by reducing stress and encouraging blood flow. Sunflower seed oil: Sunflower oil contains vitamin E, oleic acid, linoleic acid, and sesamol which are all good for your skin. It can help repair your skin barrier and reduce inflammation. Tea tree oil: Tea tree oil can reduce eczema symptoms because it has anti-inflammatory, antimicrobial, and antioxidant properties.
Yahoo
2 hours ago
- Yahoo
The Blueberry Recall Just Got More Serious—Here's What To Know
When the Fourth of July rolls around, there's nothing we love more than concocting the perfect, summery sweet treat. However, before you turn to the fruit aisle to grab fresh, seasonal strawberries and blueberries to bring to life that festive American flag cake that's every Pinterest lover's dream or that refreshing fruit salad, think twice. The FDA has issued a recall of hundreds of boxes of blueberries. Here, everything we know and what you ought to know ahead of the holiday weekend. Back in early June, a recall was issued by Georgia-based company Alma Pak International LLC for hundreds of boxes of organic blueberries. As stated by the initial report, the recall came to be when, during routine testing, the product tested positive for Listeria monocytogenes. In total, 400 30-pound boxes were part of this recall, identifiable by Lot numbers 13325 G1060 and 13325 G1096. The voluntary recall stated that these products were shipped to one customer in North Carolina. Though it was on June 9 that this recall was first issued, on July 1, the FDA elevated this situation to a Class I threat. As stated by their website, a Class I recall is 'a situation in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death.' While there have yet to be any reports of people falling ill after consuming this particular recalled product, vigilance is key when it comes to food safety. Over the last year, listeria is the word that's been circulating when it comes to recalls, and the symptoms can range from mild to severe. According to the FDA's website, the less severe version of the illness is non-invasive and usually will result in side effects like nausea, vomiting, fever, aches and diarrhea. On the contrary, the invasive version can be fatal. 'Symptoms may include headache, stiff neck, confusion, loss of balance, and convulsions,' says the FDA website. 'Invasive listeriosis is a potentially life-threatening event, especially for newborns, adults over the age of 65, and those with weakened immune systems.' If you think you might have consumed contaminated food, it's best to see your healthcare provider and monitor symptoms. If you start to feel any of the symptoms listed above, seek medical guidance. In a statement to Newsweek, the company revealed that the recall was issued before blueberries even hit shelves, meaning no customers consumed these contaminated products, and therefore, no one was at risk. They continued, 'The company worked in close coordination with the U.S. Food and Drug Administration (FDA), the Georgia Department of Agriculture, and an independent food safety consultant to conduct a thorough investigation. Alma Pak International has implemented additional corrective actions and preventive controls to further strengthen its already rigorous food safety systems.' Looking for more trending stories? Click through below! Could '1969' Be the Next 'Yellowstone' Series? Rumors Fly About a Prequel Between '1944' and Today From Tax Breaks to Medicaid Cuts: What the 'Big Beautiful Bill' Means for Americans 50+ Paula Deen's 5 Favorite Fourth of July Recipes—Drinks, Desserts & Deviled Eggs, Oh My! (EXCLUSIVE)
Yahoo
5 hours ago
- Yahoo
Theratechnologies shares surge 25% amid $254m Future Pak takeover
Contract manufacturer Future Pak will acquire Theratechnologies in a $254m deal, bringing an end to a drawn-out sale process of the Canadian HIV-specialist biopharma. Via its affiliate CB Biotechnology, US-headquartered Future Pak will purchase shares in Theratechnologies for $3.01 each plus a contingent value right (CVR) of $1.19 on the achievement of future milestones. Shares in Theratechnologies increased 25% at market open following the takeover announcement. The drugmaker has a market cap of $144.6m. The transaction, which will bring the currently Nasdaq-listed Theratechnologies back under private ownership, means Future Pak is paying a cash premium of 126% on the last closing share price for the biopharma. Theratechnologies has two products in the HIV arena that are approved by the US Food and Drug Administration (FDA), namely Egrifta (tesamorelin F8) and Trogarzo (ibalizumab-uiyk). Egrifta is approved to reduce excess visceral abdominal fat in adults with HIV and lipodystrophy while Trogarzo is indicated for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug resistance. Egrifta WR took over from Egrifta SV in March 2025, offering a more convenient formulation. Expected to close in Q4, the deal will close a sale process that has fluctuated over the past year. Future Pak's first attempt to acquire Theratechnologies was rebuffed in August 2024, with the biopharma deeming the $100m offer too low. Future Pak returned to the deal table in January 2025. Theratechnologies had already entered an exclusivity agreement with another potential acquirer, meaning Future Pak was once again turned away. Theratechnologies eventually opened the sale process to other parties, opening the door for a potential deal with the contract manufacturer. In April 2025, Future Pak tabled a $255 offer, which has now been accepted by the drugmaker. Theratechnologies reported 2024 revenue of $85.9m, a 5% increase from the $81.8m accumulated in 2023. Whilst the company reported a positive EBITDA for the year, it struggled with supply for Egrifta WR due to an issue with a contract manufacturer. Still, sales of the drug grew 12%, unlike Trogarzo, which dropped 8% due to 'competitive pressures' in the multidrug-resistant segment of the HIV market. 'This transaction is the result of a thorough and deliberate sale process aimed at maximising value for our shareholders,' stated Frank Holler, Theratechnologies' chair of the board of directors. 'Future Pak's interest in acquiring Theratechnologies represents a vote of confidence in the company we've built, recognising our achievements in bringing innovative medicines to patients and the outstanding contributions of our dedicated employees.' Last year, Future Pak also made multiple unsuccessful attempts to acquire Vanda Pharmaceuticals, the developer of sleep disorder drug Hetlioz. Cycle Therapeutics ultimately won out, acquiring in a $466m deal. "Theratechnologies shares surge 25% amid $254m Future Pak takeover" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
